Advertisement
Advertisement
GSK
GSK plc - ADR
56.67
USDSponsored
+0.68
+1.22%
Apr 02, 15:59 UTC -4
Closed
After-Market
56.60
-0.07
-0.12%
GSK Earnings Reports
Positive Surprise Ratio
GSK beat 33 of 40 last estimates.
83%
Next Report
Date of Next Report
Apr 29, 2026
Estimate for Q1 26 (Revenue/ EPS)
$7.90B
/$0.44
Implied change from Q4 25 (Revenue/ EPS)
-8.36%
/+76.00%
Implied change from Q1 25 (Revenue/ EPS)
+5.07%
/--
GSK plc - ADR earnings per share and revenue
On Feb 04, 2026, GSK reported earnings of 0.25 USD per share (EPS) for Q4 25, beating the estimate of 0.23 USD, resulting in a 8.70% surprise. Revenue reached 8.62 billion, compared to an expected 8.73 billion, with a -1.24% difference. The market reacted with a +7.29% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 5 analysts forecast an EPS of 0.44 USD, with revenue projected to reach 7.90 billion USD, implying an increase of 76.00% EPS, and decrease of -8.36% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Nanobiotix S.A. - ADR
Report Date
Mar 31, 2026 For Q4 25
Estimate
$0.55
Actual
-$0.39
Surprise
-170.16%
Pharvaris N.V. Ordinary Shares
Report Date
Apr 02, 2026 For Q4 25
Estimate
-$0.63
Actual
-$0.72
Surprise
-13.69%
Innate Pharma S.A. ADS
Report Date
Apr 01, 2026 For Q1 26
Estimate
-$0.12
Actual
-$0.55
Surprise
-353.80%
Cyclerion Therapeutics, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.38
Actual
-$0.21
Surprise
+45.82%
Femasys Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.01
Surprise
+88.80%
Kairos Pharma, Ltd.
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.05
Actual
-$0.07
Surprise
-28.68%
Soligenix, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.57
Actual
-$0.28
Surprise
+50.98%
Imunon, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$1.19
Actual
-$2.02
Surprise
-68.69%
BioAtla, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.24
Actual
-$0.16
Surprise
+34.64%
CNS Pharmaceuticals, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$5.19
Actual
-$10.15
Surprise
-95.50%
FAQ
What were GSK plc - ADR's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, GSK plc - ADR reported EPS of $0.25, beating estimates by 8.7%, and revenue of $8.62B, -1.24% below expectations.
How did the market react to GSK plc - ADR's Q4 2025 earnings?
The stock price moved up 7.29%, changed from $53.34 before the earnings release to $57.23 the day after.
When is GSK plc - ADR expected to report next?
The next earning report is scheduled for Apr 29, 2026.
What are the forecasts for GSK plc - ADR's next earnings report?
Based on 5
analysts, GSK plc - ADR is expected to report EPS of $0.44 and revenue of $7.90B for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement